Generic Name and Formulations:
Erythromycin (as base) 250mg; e-c pellets in caps.
Warner Chilcott Laboratories
Indications for ERYC:
Susceptible infections including upper and lower respiratory, skin and soft tissue, genitourinary, Legionnaires' disease, pertussis, listeriosis.
250mg every 6 hours 1 hour before meals; max 4g daily. Legionnaires: 1–4g/day in divided doses.
Mild-to-moderate infections: 30–50mg/kg/day in divided doses 1 hour before meals; may double dose in severe infections.
Concomitant cisapride, pimozide, ergotamine, dihydroergotamine.
Hepatic dysfunction. Proarrhythmic conditions (eg, uncorrected hypokalemia or hypomagnesemia, clinically significant bradycardia); QT prolongation may occur, avoid. Myasthenia gravis. Elderly. Pregnancy (Cat.B). Nursing mothers.
See Contraindications. May potentiate or be potentiated by drugs metabolized by CYP3A (eg, carbamazepine, cyclosporine, tacrolimus, alfentanil, disopyramide, bromocriptine, rifabutin, quinidine, methylprednisolone, cilostazol, vinblastine). May potentiate or be potentiated by hexobarbital, phenytoin, valproate. May potentiate triazolam, midazolam, digoxin, theophylline, statins (rhabdomyolysis), sildenafil (reduce dose of sildenafil), colchicine (reduce starting dose of colchicine, max dose should be lowered; monitor). Hypotension, bradyarrhythmias, lactic acidosis with verapamil. Hypotension with calcium channel blockers metabolized by CYP3A4 (eg, verapamil, amlodipine, diltiazem). Increased anticoagulant effects with oral anticoagulants. QT prolongation with concomitant Class 1A (quinidine, procainamide) or Class III (dofetilide, amiodarone, sotalol) antiarrhythmics. May interfere with fluorometric detection of urinary catecholamines.
GI upset, abdominal pain, anorexia, hepatic dysfunction; QT prolongation.